New Oral Anticoagulants: A Balancing Act Between Safety and Efficacy

Sunday, December 2, 2012
3:30 PM – 5:00 PM

Planned in cooperation with the ASHP New Practitioners Forum and the ASHP Section of Clinical Specialists and Scientists
Activity #: 204-000-12-309-L01P
Level of Content: Advanced
1.50 Contact Hours / Knowledge-based
Program Chair: Joel C. Marrs, PharmD, BCPS

Learning Objectives:

• Describe safety data comparing the bleeding risk between warfarin, dabigatrin, and rivaroxaban.
  
• Compare anticoagulation reversibility practices between warfarin, dabigatran, and rivaroxaban.
  
• Describe stroke prevention data in patients with nonvalvular atrial fibrillation treated with warfarin, dabigatrin, or rivaroxaban.
  
• Determine optimal practices for the safe use of new oral anticoagulants in the inpatient setting and the transition to outpatient setting